Louisa Temme

Louisa Temme

Auto-generated profile, based on publicly available information

Louisa Temme

University of Hamburg

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in ChemMedChem
Verified
Journal Article
Closed access
CAChristopher R. M. Asquith
Christopher R. M. Asquith
LTLouisa Temme
Louisa Temme
MEMichael P. East
Michael P. East
TLTuomo Laitinen
Tuomo Laitinen
JPJulie Pickett
Julie Pickett
David DrewryDavid Drewry
David Drewry

25 June 2020 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
CAChristopher R. M. Asquith
Christopher R. M. Asquith
LTLouisa Temme
Louisa Temme

28 December 2020 in ChemRxiv
Verified
Preprint
Open access
BEBenjamin Eduful
Benjamin Eduful
SOSean O'Byrne
Sean O'Byrne
LTLouisa Temme
Louisa Temme
CAChristopher R. M. Asquith
Christopher R. M. Asquith
YLYi Liang
Yi Liang
David DrewryDavid Drewry
David Drewry
CAMKK2 is a serine/threonine kinase and an activator of AMPK whose dysregulation is linked with multiple diseases. Unfortunately, STO-609, the tool inhibitor commonly used to probe CAMKK2 signaling, has limitations. To identify promising scaffolds as starting points for the development of high-quality CAMKK2 chemical probes, we utilized a hinge-binding scaffold hopping strategy to design new CAMKK2 inhibitors. Starting from the potent but promiscuous disubstituted 7-azaindole GSK650934 (CAMKK2 IC50 = 3 nM), a total of 32 compounds, composed of single ring, 5,6-, and 6,6-fused heteroaromatic cores were synthesized. The compound set was specifically designed to probe interactions with the kinase hinge-binding residues. These compounds were evaluated in vitro in biochemical and cellular assays for CAMKK2 inhibition. Compared to GSK650394 and STO-609, thirteen of our compounds displayed similar or better CAMKK2 inhibitory potency in vitro, while compounds 13g and 45 had greatly improved selectivity for CAMKK2 across the kinome. Our systematic survey of hinge binding chemotypes identified several potent and selective inhibitors of CAMKK2 to serve as starting points for medicinal chemistry programs aimed at the identification of CAMKK2 chemical probes and clinical candidates

31 August 2026 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
TMTeresa Mittermair
Teresa Mittermair
JMJens MünChow
Jens MünChow
TSTimo StrünKer
Timo StrünKer
LTLouisa Temme
Louisa Temme
CBChristoph Brenker
Christoph Brenker
The sperm-specific K+ channel Slo3 is required for sperm function and fertilization in mice and humans. Due to the lack of selective pharmacological tools, its molecular and cellular physiology in human sperm has remained only ill-defined, though. The compound VU0546110 (1) was recently introduced as the first selective Slo3 inhibitor and is now being used to study the channel’s role in human sperm. Whether the compound may have off-target actions in sperm is however unknown. Here, using kinetic Ca2+ fluorimetry, patch-clamp recordings, and sperm from infertile men with a homozygous deletion of the CATSPER2 gene as experimental model, we show that VU0546110 simultaneously inhibits Slo3 and activates the sperm-specific Ca2+ channel CatSper. This demonstrates that the utility of the drug is limited: it is difficult to decipher if its action on human sperm is due to inhibition of Slo3, activation of CatSper, or a combination of both. We also introduce derivatives of VU0546110 that show a reduced potency and efficacy for CatSper activation, while preserving the inhibitory action on Slo3.

18 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MEMadison Edwards
Madison Edwards
AAAlexandra Amaral
Alexandra Amaral
ECEve M. Carter
Eve M. Carter
OAOliver Arnolds
Oliver Arnolds
KVKaren Vester
Karen Vester
CTClaudia Tredup
Claudia Tredup
Study question: Is the hydrolase ABHD2 required for progesterone-induced Ca 2+ influx via CatSper and the resulting motility responses in human sperm? Summary answer: Progesterone-induced Ca 2+ influx via CatSper and the resulting motility responses in human sperm do not require ABHD2 activity. What is known already: Sperm motility is tightly regulated by signalling pathways that are activated as sperm ascend the female reproductive tract, including progesterone triggering Ca 2+ influx via the CatSper channel and inducing hyperactivated motility needed for fertilization. This process is thought to involve ABHD2, which may hydrolyse the endogenous CatSper inhibitor 2-arachidonoylglycerol (2-AG), thereby relieving inhibition and enabling calcium entry into the flagellum. Study design, size, duration: Potent small molecule inhibitors of ABHD2 activity were synthesized, characterized, and used as tools to scrutinize the role of ABHD2 in activation of CatSper and regulation of sperm motility. Participants/materials, setting, methods: Derivatives of published ABHD2 inhibitors were optimised for in vitro potency and cellular activity and subsequently tested in human sperm motility and Ca 2+ influx assays. Main results and the role of chance: Progesterone does not activate ABHD2 in vitro. In addition, inhibition of ABHD2 in human sperm has no effect on progesterone-induced Ca 2+ influx through CatSper nor on basal or progesterone-induced hyperactivated motility. This demonstrates that ABHD2 activity is, in fact, not required for the non-genomic action of progesterone on human sperm. Large scale data: none Limitations, reasons for caution: We examined the effects of inhibition of the enzymatic activity of ABHD2. We cannot exclude that ABHD2 functions as a part of a larger multiprotein complex, in which it may play a structural role independent of its hydrolase activity. Wider implications of the findings: This study presents conclusive evidence that ABHD2 does not bind progesterone and that its hydrolase activity is not required for progesterone activation of CatSper and resulting changes in motility of human sperm. These results highlight the need for further research to elucidate the mechanism underlying the non-genomic action of progesterone on human sperm. Study funding/competing interest(s): This publication is based on research funded by the Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Gates Foundation. LT, CB, and TS were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - project numbers 329621271 (CRU326; CB, TS), and 404595355 (Research Training Group “Chemical biology of ion channels (Chembion)’; LT, TS). This work was funded by the German Federal Ministry of Education and Research (BMBF) within the framework of Contraception Research, grant number 01GR2501A and 01GR2502A. A.A., K.V., A.T., N.D., A.H., M.W. and R.L. are employees of Nuvisan ICB GMBH, Berlin, Germany. Nuvisan is recipient of a Gates Foundation grant. A.A is associate editor of Human Reproduction Open.